It is easy for speculators to salivate over soaring biotech stocks, but when things go wrong, they will go very wrong. A hold on a clinical study for Juno Therapeutics (JUNO) on July 7 caused the stock to fall 32 percent. Two subjects died after receiving JCAR015, which treats relapsed or refractory B cell acute lymphoblastic leukemia." In a call with analysts, Juno CEO Hans Bishop said that the company no longer expects to get the drug on the market in 2017. That deadline has now been pushed to 2018. He also said that another patient had died of neural toxicity in May, but the study continued after discussions with the FDA.”Shareholders of Kite Pharmaceuticals (KITE) are down on this news. Fludarabine is part of the pre-treatment procedure with CAR-T.CAR-T is too novel a treatment option. In time, the company will figure out the right drug mix.